logo

AMLX

Amylyx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

AMLX fundamentals

Amylyx (AMLX) released its earnings on Nov 6, 2025: revenue was 0 (YoY -100.00%), beat estimates; EPS was -0.37 (YoY +30.19%), beat estimates.
Revenue / YoY
0
-100.00%
EPS / YoY
-0.37
+30.19%
Report date
Nov 6, 2025
AMLX Earnings Call Summary for Q3,2025
  • LUCIDITY Trial Update: Enrollment completion now expected in Q1 2026, with top-line data in Q3 2026. Avexitide remains on track for a 2027 launch pending FDA approval.
  • Financial Strength: $344 million cash position supports a 2028 runway. Operating expenses down 53% YoY, driven by reduced pipeline spending.
  • Pipeline Progress: Gubra collaboration for a long-acting GLP-1 antagonist nearing candidate nomination. AMX0035 pivotal trial initiation in H2 2026 pending FDA alignment.
  • Market Focus: 160,000 PBH patients in the U.S., with unmet need driving avexitide's development and commercial readiness.
EPS
Revenue

Revenue & Expenses

Key Indicators

Amylyx (AMLX) key financial stats and ratios, covering profitability, financial health, and leverage.
Amylyx (AMLX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Amylyx (AMLX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Amylyx (AMLX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Amylyx (AMLX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Amylyx (AMLX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield